NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Dabigatran etexilate for the prevention of stroke or systemic embolism in atrial fibrillation

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:					
Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:					
	Proposal:	Proposal made by:		Action taken: Removed/Added/Not included/Noted	Justification:
1.	Please include Xarelto (rivaroxaban) in the list of potential comparator manufacturers.	Bayer		Noted.	NICE believes that these are not relevant comparators and therefore shall not be added to the matrix.
2.	Add Anticoagulation Specialist Association (ASA) to professional groups.	Boehringer Ingelheim Ltd		Added.	Anticoagulation Specialist Association (ASA) meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix.

3.	Add British Society for Haematology (BSH) to professional groups.	Boehringer Ingelheim Ltd	Added.	British Society for Haematology (BSH) meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix.
4.	Add British Society for Haemostasis and Thrombosis (BSHT) to professional groups.	Boehringer Ingelheim Ltd	Added.	British Society for Haemostasis and Thrombosis (BSHT) meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix.
5.	Add Clinical Leaders of Thrombosis (CLOT) to professional groups.	Boehringer Ingelheim Ltd	Added.	Clinical Leaders of Thrombosis (CLOT) meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix.
6.	Remove Age Concern England from patient/carer groups.	NICE Secretariat	Removed.	Completed as per the specific organisations request.
7.	Remove British Ethnic Health Awareness Foundation (BEHAF) from patient/carer groups.	NICE Secretariat	Removed.	British Ethnic Health Awareness Foundation (BEHAF) has been removed from the Charity Commission records and therefore doesn't meet the inclusion criteria.
8.	Add Royal Pharmaceutical Society to professional groups.	NICE Secretariat	Added.	The Royal Pharmaceutical Society meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a professional group consultee.

Consultation comments on the matrix for appraisal of dabigatran etexilate for the prevention of stroke or systemic embolism in atrial fibrillation. Issue date: March 2010

9.	Add Commissioning Support Appraisals Service to general commentators.	NICE Secretariat	Added.	The Commissioning Support Appraisals Service meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a general commentator.
10.	Remove Age Concern Cymru from general commentators.	NICE Secretariat	Removed.	Completed as per the specific organisations request.
11.	Add MRC Clinical Trials Unit to relevant research groups.	NICE Secretariat	Added.	The MRC Clinical Trials Unit meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a relevant research group commentator.
12.	Remove United Kingdom Clinical Research Network from relevant research groups.	NICE Secretariat	Removed.	The United Kingdom Clinical Research Network is a part of the National Institute for Health Research as per inclusion criteria an organisation is listed only once therefore they have been removed from the matrix.
13.	Remove Confederation of Indian Organisations from patient/carer group consultees.	NICE Secretariat	Removed.	Confederation of Indian Organisations have now closed, and therefore been removed from the matrix.

Consultation comments on the matrix for appraisal of dabigatran etexilate for the prevention of stroke or systemic embolism in atrial fibrillation. Issue date: March 2010

14.	Remove Help the Aged from patient/carer group consultees.	NICE Secretariat	Removed.	Completed as per the specific organisations request.
15.	Add Atrial Fibrillation Association (AFA) to patient/carer group consultees.	NICE Secretariat	Added.	Atrial Fibrillation Association (AFA) meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix.

Issue date: March 2010